Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.76 |
| ▸ | MAOB | P27338 | 6/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SDHA | P31040 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CALML3 | P27482 | 1/20 | 0.76 |
| ▸ | F10 | P00742 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811281 | 1.00 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6735636 | 0.94 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6735633 | 0.94 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3185881 | 0.94 | MAOA (0.82) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3568166 | 0.94 | MAOA (0.82) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6615781 | 0.92 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6615783 | 0.92 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987847 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987852 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7818282 | 0.89 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883093-A | TREATING MICROBIAL INFECTIONS IN WARM BLOODED ANIMALS, INCLUDING HUMANS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-16 | — | — | US | claimed |
| EP-1443108-A2 | Processes for preparing reconstructed skin supplemented in ceramid 7 and/or 5.5, composition based on lamellar lipid vesicles comprising a derivative of ceramid 7 and/or 5.5 and use thereof | L'OREAL (FR) | 2004-08-04 | — | — | EP | disclosed |
| US-20040087633-A1 | Methylidene oxazolidinone compound and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-05-06 | — | — | US | disclosed |
| EP-0788498-B1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2001-08-16 | — | — | EP | disclosed |
| US-5883093-A | TREATING MICROBIAL INFECTIONS IN WARM BLOODED ANIMALS, INCLUDING HUMANS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0788498-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013502-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087633-A1 | Methylidene oxazolidinone compound and preparation method thereof | OXA1L, TET1, TET2 | MAOA 3034/4885MAOB 2369/4885PTGS1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.